SCHEMBL3763748

SCHEMBL3763748

CC(C)(C)OC(=O)N(C(=O)N1CCCCC1)c1[c]cccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
ALDH1A1 P00352 2/20 0.37
POLB P06746 2/20 0.37
HPGD P15428 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ABL1 P00519 1/20 0.35
RIN1 Q13671 1/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760642 0.88 MAPK1 (0.39) GPR119POLBHPGDCHRM2CHRM4
SCHEMBL3760364 0.80 AKT1 (0.36) GPR119MAPTMEN1KMT2AABL1
SCHEMBL3763750 0.80 MAPT (0.38) GPR119SMN1; SMN2ALDH1A1POLBHPGD
SCHEMBL3765395 0.76 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1POLBHPGDNPC1
SCHEMBL3765356 0.74 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1POLBHPGDNPC1
SCHEMBL8668359 0.74 PAX8 (0.40) GPR119ALDH1A1POLBRAB9AMEN1
SCHEMBL3769539 0.73 DPP7 (0.36) GPR119SMN1; SMN2ALDH1A1HPGDNPC1
SCHEMBL3759116 0.72 ALDH1A1 (0.61) SMN1; SMN2ALDH1A1POLBHPGDNPC1
SCHEMBL5730363 0.70 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1HPGDNPC1RAB9A
SCHEMBL6497833 0.69 HPGD (0.44) SMN1; SMN2ALDH1A1HPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA GPR119 1143/4885SMN1; SMN2 1864/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.